protocol IntroDuctIon
Numerous genetic alterations are associated with the development and progression of pancreatic cancer 1 . However, the spectrum of genetic and epigenetic changes and the role of the tumor micro environment in this process remain poorly understood. Lack of this understanding stems, in part, from deficiencies in the model sys tems used to study the disease. Therefore, an increasing awareness has developed regarding the necessity for new models of pancreatic cancer that better incorporate the complex factors that promote tumor progression and metastasis. One popular strategy in this regard is the development of transgenic mouse models of pan creatic cancer. Such genetic models hold much promise both for studying early disease progression and for screening of new thera peutics, especially potential chemopreventive agents [2] [3] [4] . However, to date, the utility of transgenic mouse models remains limited in the study of latestage disease because of their inability to faithfully recapitulate the complete cascade of events in tumor cell invasion and metastasis to distant organs 5 . Another strategy gaining recent interest involves the direct implantation of primary tumor samples from patients into immunodeficient mice at the time of surgical resection [6] [7] [8] [9] . Models resulting from this approach use human tumors and recapitulate many tumor/microenvironment interac tions, retain important genetic features while maintaining tumor heterogeneity and often develop distant metastases [6] [7] [8] [9] . We herein focus on the requirements to optimize tumor development by this latter strategy in heterotopic (extrapancreatic) and orthotopic (intrapancreatic) sites, as well as from traditional cell lines that are still used by many investigators (Fig. 1) .
Several types of immunodeficient mice have been used to grow xenograft tumors. Athymic nude mice (Tcell deficient) have proven useful for the establishment of xenograft tumors both from patients' tumor samples and established human cancer cell lines [10] [11] [12] . Reduced cost, widespread availability and the absence of fur have offered investigators convenient access to these useful in vivo tumor models of human cancers. However, intact humoral immunity in nude mice results in reduced efficiency of tumor for mation relative to mice with severe combined immunodeficiencies (SCID mice-lack functional T and B cells), particularly in cases of low cell inoculum 13 . Furthermore, nonobese diabetic (NOD)/SCID mice harboring additional deficiencies in natural killer cells (NOD/ SCID Il2rg − / − ) have permitted tumor establishment from even fewer numbers of tumor cells than previously observed in NOD/ SCID and nude mice 14, 15 . Thus, nude mice, even with their limited immunity, may select for subsets of tumor cells that reduce tumor heterogeneity and the biological complexity present in the original human tumor. Nevertheless, both athymic nude and NOD/SCID mice continue to be used widely for molecular and translational studies of human cancers.
Besides differences in mouse hosts, established cancer cell lines are easily implanted into mice at heterotopic or orthotopic sites and can be serially passaged into congenic mouse strains with excellent efficiency. Such tumors now are frequently termed 'indi rect xenografts' because of long periods of cancer cell growth (often decades) between acquisition from patients and animal implan tation. Indirect xenografts continue to be extensively used and offer convenience in cell manipulation with limited technical skill required for successful engraftment. However, indirect xenograft models inconsistently predict the efficacy of novel therapeutics in selected human tumors, including pancreatic cancer [16] [17] [18] [19] . To some degree, this inability to predict clinical efficacy stems from poor experimental design, e.g., the initiation of therapeutic treatment within a few days of tumor cell inoculation. Additional problems that lead to the poor predictive capability of indirect xenografts likely include longterm selection for growth in culture media rather than in a host environment, and a relative paucity of peri tumoral stroma. Furthermore, most tumors are generated from a large inocula of tumor cells, subverting the natural processes of genetic and epigenetic progression that occur from small, clonal tumors. 
protocol
In response to these and other concerns, models initiated by direct heterotopic and/or orthotopic engraftment of primary human tumor samples into immunodeficient mice are receiv ing increasing interest. Such direct xenograft models generated directly from tumor samples of patients without a cell line inter mediary have been termed 'tumorgrafts' for this distinction 20 . This approach may better preserve tumor heterogeneity and limit the ex vivo manipulation inherent in the culturing of cancer cell lines. Most direct xenograft tumors grow with considerable stromal ele ments and recapitulate the histological appearance of the original patient tumor over multiple passages in mice ( Fig. 2) (refs. 8,9,21) . Published data indicate that when used appropriately, direct xeno graft models reliably predict clinical response in pediatric malig nancies 22, 23 . Similarly, studies indicate that direct pancreatic cancer xenografts may be used to effectively screen therapeutic agents when heterotopically implanted in nude mice 8, 24 . Direct xenografts have also been used to identify and enrich distinct subpopulations of cells, such as tumorinitiating cells (cancer stem cells), from various solid organ tumors [25] [26] [27] . However, the degree to which direct xenografts reflect the biology of primary pancreatic tumors when grown in mice remains unknown. Furthermore, differences related to the site of human tumor implantation (heterotopic versus orthotopic) may also affect the biology of xenograft tumors and, at present, require further study.
In efforts to incorporate all relevant models of pancreatic can cer into our studies, we have developed a direct pancreatic cancer xenograft program 28 . The value of such a program is reflected in its inherent versatility; direct xenograft models may be used to study diverse aspects of cancer biology including drug resistance, angiogenesis, tumor microenvironment, cancer stem cells and experimental therapeutics. We detail below our protocols for the orthotopic and heterotopic implantation of primary patient tumor samples, direct pancreatic cancer xenografts and established pan creatic cancer cell lines. Furthermore, owing to widespread emerg ing interest in the isolation of subpopulations of cancer cells, we describe our method for the processing of bulk tumor samples into singlecell suspensions that can then be used for the analysis by flow cytometry and cell sorting 29 (M.P.K., J.B.F., D.B.E., H.W. and G.E.G., unpublished observations).
Experimental design Immunodeficient mice. Immunodeficient mice should be housed under specific pathogenfree conditions to prevent sickness and infectious outbreak. After tumor implantation, mice should be monitored daily for signs of illness and surgical wounds assessed for infection. The presence of ruffled fur, lethargy and tachypnea are principal signs of animal sickness. Accordingly, after the implantation of human cancer cells, we obtain weekly body weights on all immunodeficient mice to track changes in general health. Given their susceptibility to pathogens, strict sterile tech nique must be observed at all times when working with immuno deficient mice.
Tumors derived from human pancreatic cancer cells may be established in various immunodeficient mice. Athymic nude mice have traditionally been used to grow tumors of human origin and are readily available. These mice lack fur, are easy to manipulate and are tolerant of anesthesia and surgical procedures. Relative to nude mice, NOD/SCID mice are more expensive and immunodeficient, resulting in an increased incidence of surgical, anesthetic and infec tious complications. It is important to know that differences relat ing to clonal selection, heterogeneity and cancer cell proliferation may exist between tumors formed in nude and NOD/SCID mice and would require additional study.
In our experience, NOD/SCID mice are superior in the efficiency of tumor formation and are less likely to impart selective pressures against implanted human tumors. We therefore favor the exclusive use of NOD/SCID mice in all studies involving direct xenograft tumors. As established pancreatic cell lines are already products of longterm selection, we use athymic nude mice in studies involving indirect (cell line based) xenograft tumors. Within weeks after implantation of human pancreatic cancer cell lines (>250,000 cells), young ( < 10 weeks) athymic nude mice reliably form tumors. 11 . Furthermore, some pancreatic cancer cell lines are known to metastasize more frequently than others and should be considered when studying metastatic outcomes 30 .
Manipulation of human pancreatic tumors (surgical specimens).
Human pancreatic tumors from surgical specimens should be acquired under the strict supervision of staff pathologist(s) to maintain patient care and to ensure adequate tissue diagnosis. Accordingly, a direct transfer of human pancreatic tumors into immunodeficient mice requires institutional review board as well as Institutional Animal Care and Use Committee (IACUC) approval and must be conducted in accordance with institutional and national regulations. Principal determinants of successful tumor engraftment into immunodeficient mice are the viability and sterility of the human tumor. Consequently, optimal handling of human tumor tis sue should minimize warmischemia time and bacterial/fungal contamination. Tumor tissue should be maintained in serum free antibiotic media and kept at 4 °C on ice as much as possible. Manipulation of surgical specimens should also be performed sterile, using a sterile hood, sterile instruments, containers, etc. Ideally, specimens should be implanted into mice < 1 h after resection.
Implantation site. Pancreatic cancer cells may be implanted outside the mouse pancreas (heterotopically) or directly into the mouse pancreas (orthotopically) and monitored for tumor formation. Many different properties may then be assessed according to experimental objectives including local invasion, metastasis, response to therapeutic agents and so on 11, 12, 31, 32 . Commonly, investigators will alter the expression of select genes in established cancer cell lines, engraft these cells into immunodeficient mice and assess for similar outcomes 11 .
Relative to the orthotopic implantation of pancreatic cancer cells, the principal benefits of heterotopic implantation include ease of cell implantation (subcutaneous), accurate monitoring and measurement of tumor size, and a lower incidence of proce dural complications. Orthotopic implantation of pancreatic cancer cells is more timeconsuming, technically challenging and often requires ultrasound examinations or exploratory laparotomies to exclude or confirm the presence of tumor. However, the external milieu is more closely preserved in orthotopic tumors and theoreti cally better approximates the 'natural' setting of pancreatic cancer. Consequently, we favor the orthotopic implantation of pancreatic cancer cell lines and direct xenograft tumors under most experi mental conditions.
Initial engraftment of human primary pancreatic tumors.
Human pancreatic tumor tissue directly isolated from surgi cal specimens may be implanted into immunodeficient mice in the form of small tumor fragments or cell suspensions, at either heterotopic or orthotopic sites. Orthotopic implantation of primary patient tumor specimens requires digestion of the acquired tumor into singlecell suspensions. To obtain a reasonable cell yield after tumor digestion, we only attempt digestion of patient tumor when substantial quantities of excess surgical specimens are available for research (>1.5 to 2 g). To maximize the engraftment of small quantities of patient tumors in immunodeficient mice, we favor the initial placement of tumor into the subcutaneous space of F1 mice. Once grown, the tumor may then be digested and orthotopically implanted into subsequent generations of mice. We have found this approach to maximize the engraftment of small patient specimens and/or treated tumor while greatly expanding the amount of F1 tumor available for study and mouse passage. Otherwise, to maxi mize the incidence of tumor growth after initial implantation into immunodeficient mice, patient tumor fragments can be routinely implanted into heterotopic sites. If sufficient patient tumor speci men is available, we prefer to implant primary tumor fragments into five NOD/SCID mice to ensure xenograft tumor growth from at least one mouse (engraftment rates may range as low as 20%). Once heterotopic xenograft tumors have formed, then there is ample tumor available for digestion into singlecell suspensions and subsequent orthotopic and/or heterotopic implantation.
Alternatively, tumor fragments from surgical specimens may be embedded within the pancreatic parenchyma, as published previ ously 6 . Our experience with this technique is limited as it largely precludes the analysis and isolation of cell subpopulations from primary patient tumor specimens. However, this method has been shown to increase the incidence of liver metastases associated with xenograft growth, and should be considered when metastases are important experimental outcomes 6, 24 .
Maintenance of direct xenograft tumors. Direct xenograft tumors may be maintained in immunodeficient mice through their passage into successive mouse generations. Depending on the experimental objectives, the passage of grown xenograft tumor into recipient mice may occur at heterotopic and/or orthotopic sites and as tumor fragments or digested tumor cell suspensions. Similar to cell lines, heterotopic (subcutaneous) tumor formation permits the easy measurement of tumor size and response to therapeutic agents while limiting technical complications involved in tumor establishment. Importantly, mice should be killed and the tumor harvested before it reaches a diameter of 1.5 cm. Similarly, in our experience, the minimum tumor size for a successful passage is ~0.3 cm.
To maintain and expand tumor derived from a specific xenograft 'line' , we routinely propagate heterotopic tumors. This practice effectively amplifies the quantity of biospecimen available for study and when stored, either in paraffin blocks or as frozen tissues, provides a valuable future resource. Present and future experimental considerations should therefore dictate the location, extent and method of tumor passage and maintenance.
Digestion of tumor into a single-cell suspension. Xenograft tumors should be carefully dissected from the killed mouse hosts to minimize contamination with cells of mouse origin. To main tain sterility, we shave the tumor site using electric clippers and paint it with 70% ethanol before skin incision. Once complete, we use freshly autoclaved surgical instruments to incise the skin and to dissect tumor from all adherent tissue. Once free, tumor is transferred to the inverted lid of a sterile multiwell plate for further Tumor is minced with sterile scalpels while still on the inverted multiwell plate lid. Typically, 2 ml of collagenase solution is directly added to the tumor during mincing to prevent desiccation of tumor fragments and to facilitate tumor dissociation. Persistent mincing will reduce the tumor tissue to a pastelike consistency, at which time 0.2g portions should be individually placed into the wells of sixwell plates. Importantly, the quantity of collagenase solution should be prepared based on the weight of xenograft tumor. As 5 ml of collagenase solution is added to an individual well contain ing 0.2 g of tumor, we prepare 6 ml of collagenase solution per 0.2 g of tumor to ensure a sufficient amount of collagenase solution.
We have found that digestion of tumors into singlecell suspen sions sometimes requires changes in collagenase incubation time and/or collagenase concentration to maximize cell yield. Incomplete tumor digestion manifests as poor cell yield, cell clusters/intact tumor on microscopic examination, and/or a thick, viscous cell suspension, and specific conditions should be applied to augment the dissociation of tumor. We initially increase incubation times of tumor in collagenase solution to 6-8 h and filter the resultant cell solution thrice through sterile 40µm nylon filters. Cell yield and viability are then assessed through trypan blue exclusion and if additional digestion is required, we next double the concentra tion of collagenase. In our experience, once digestion conditions have been optimized for a direct xenograft tumor, all other tumors derived from the same patient tissue respond similarly and should be digested using identical conditions. Orthotopic implantation of pancreatic cancer cells. Suspen sions containing cells derived from patient samples or established cell lines should be injected into the head/neck region of the mouse pancreas. Typically, we suspend 500,000 cells in 100-150 µl of serumfree media and prepare at least twice the amount of cell suspension needed for experiments. Pancreatic injections in control mice should contain only the suspension media without cells.
Importantly, there is a tendency for fluid to leak from the needle site after the injection of cell solution that can result in peritoneal spread and carcinomatosis. Therefore, it is important to mini mize the volume of cell solution injected into the pancreas and to monitor the injection site for gross leakage after withdrawal of the needle. For users with minimaltomoderate experience in pan creatic injections, we recommend the addition of Matrigel (1% (vol/vol)) to injected cell solutions, which will immediately increase the viscosity of the injected fluid and mitigate leakage. The volume of injection may also be decreased to 50 µl, if necessary. In addi tion, repeated penetration of the pancreas by the needle should be minimized to prevent leakage of the injected cell suspension. Lastly, care should be taken to not disrupt any important vascular struc tures within the pancreas during the course of injection. Risk of vascular damage may be minimized by passing the needle parallel to any visible vessels, along the length of the pancreas.
Time until tumor formation and detection of xenograft tumors. Many factors may affect initial engraftment of human tumor into immunodeficient mice including the viability of the tumor, the sterility of the tumor specimen, pretreatment status of the patient and adherence to proper surgical technique. Initial tumor formation is considered the date when a subcutaneous nodule is initially palpated and confirmed as the nodule develops into a larger tumor 28 
Tumor formation after implantation of most established pancre atic cancer cell lines varies by cell line, site of implantation and cell inoculum. We have successfully established palpable heterotopic and orthotopic tumors from the cell lines L3.6pl, Panc1 and MiaPaCa 2-4 weeks after injection of 0.5 × 10 6 -1 × 10 6 cells 11, 12, 31, 32 .
Timing. The number of mice engrafted with tumor and their sub sequent recovery time from anesthesia may significantly alter total procedure time. We therefore recommend allotting at least twice the amount of procedure time described for initial attempts to establish and/or passage direct xenograft tumors.
Heterotopic implantation of patient tumor fragments into five immunodeficient mice takes ~1 h after the acquisition of tumor. Similarly, heterotopic implantation of direct xenograft tumor frag ments into five immunodeficient mice takes ~1 h and an addi tional 15 min for tumor harvest from host mice. Another hour is generally required for the monitoring and recovery of all mice from anesthesia.
Dissociation of patient tumor or direct xenograft tumor into single cells takes ~3 h. Importantly, this time may vary between direct xenograft tumors of different patient lineage and conditions should be optimized to maximize cell yield (see TROUBLESHOOTING). Processing and preparation of established cell lines for orthotopic or heterotopic injection generally requires 1 h. Once a singlecell suspension is obtained (either from digested tumors or from established pancreatic cancer cell lines), orthotopic injection of pancreatic cancer cells takes ~20 min per mouse with the major ity of procedure time dedicated to the proper closure of surgical incisions. Heterotopic injection of pancreatic cancer cell lines takes ~3 min/mouse. Once again, an hour should be allotted to monitor and recover all mice from anesthesia. 
MaterIals

REAGENTS
REAGENT SETUP Serum-free antibiotic media Sterile RPMI1640 media supplemented with 1% (vol/vol) Antibiotic-antimycotic (100 U ml − 1 penicillin, 100 U ml − 1 strepto mycin, 0.25 µg ml − 1 amphotericin B, final concentration). Should be prepared fresh, filtersterilized and stored at 4 °C for continued use of up to 3 weeks. Ketamine/xylazine solution Combine 2.5 ml of ketamine stock (100 mg ml − 1 ) with 0.5 ml xylazine stock (100 mg ml − 1 prepared from powder in dH 2 O) and dilute with 7 ml of distilled water. (ii) Transfer the tumor specimen into a sterile 50-ml centrifuge tube containing 30 ml of sterile, serum-free RPMI medium supplemented with 1× (vol/vol) Antibiotic-antimycotic (antibiotic media), chilled to 4 °C. ! cautIon All primary surgical specimens must be assumed biohazardous and handled with extreme caution using universal precautions. Acquire excess tumor in accordance with institutional review board guidelines and regulations only after adequate tissue diagnosis and evaluation of tumor margins have been carried out through a pathology study.  crItIcal step The time interval between tumor resection and implantation in mice must be kept to a minimum, ideally < 1 h. (iii) Wash the tumor sample twice with 30 ml of serum-free antibiotic media chilled to 4 °C in order to reduce contaminant load. (iv) Weigh a NOD/SCID mouse and anesthetize using ketamine/xylazine cocktail at a ratio of 100 mg kg − 1 :20 mg kg − 1 .
Place the mouse under a heat lamp. ! cautIon All animal experiments require approval by an institutional review board and animal use and care committees and must be conducted in accordance with institutional and national regulations. steps 1-3, Fig. 3 ). (viii) Close the incision with interrupted, 3-0 silk stitches (Fig. 4) .
(ix) Recover the mice from the effects of anesthetic.  crItIcal step Continue to monitor the temperature, skin color and respiratory rate of mice while under a heat lamp. Mice have recovered from the procedure once they are in a sternal position, respond to external stimuli and freely move about their cage. 
Box 1 | HETERoToPIC IMPLANTATIoN oF TUMoR FRAGMENTS
1. Pick up the flank skin with forceps and make a 1-cm incision in the skin at the superior aspect of the flank with using sterile, curved micro-scissors. Develop a subcutaneous pocket through insertion of the scissor tips into the subcutaneous space and a gentle spreading motion (Fig. 3a) .  crItIcal step The skin incision should involve only the skin layers and not deep muscle layers. The skin is highly mobile and identifiable when grasped with forceps and lifted from the deep tissue. 2. While holding the incision site open with forceps, gently lay five 1-mm 3 tumor fragments (prepared in Step 1A(vi)) onto the underlying muscle (Fig. 3b) . Tumor fragments should remain individually adherent to the muscle surface within the formed subcutaneous tract (Fig. 3c) .
3. Close the skin incision with interrupted 3 − 0 silk sutures and apply antibiotic ointment (Fig. 4a-c) . While gently grasping the skin with forceps for counter-traction, penetrate the skin with the needle tip at approximately a needle's length from the desired injection site. Direct the needle to the desired implantation site while passing the needle parallel to the animal's body. (xv) Confirm that the needle is in the subcutaneous space by slightly elevating the needle away from the animal, thereby stretching surrounding loose skin (a needle inserted into deep tissue will not produce this characteristic 'tenting' of skin). Slowly inject 100-150 µl of cell suspension. Successful cell injections are indicated by the subtle appearance of subcutaneous bulla.
? trouBlesHootInG (xvi) Withdraw the needle slowly from the tract and monitor for 2 min for gross leakage.
? trouBlesHootInG (xvii) Recover the mice from the effects of anesthesia.
Continue to monitor animal temperature, skin color and respiratory rate while under a heat lamp. Mice have recovered from anesthesia once they are in a sternal position, respond to external stimuli and freely move about inside the cage. 
3|
If working with direct xenograft tumor, kill tumor-bearing mouse in a CO 2 chamber and shave the tumor site using electric clippers. Paint the tumor site with 70% (vol/vol) ethanol and transfer the mouse to a sterile hood.  crItIcal step All tumor-bearing mice should be killed and the tumor harvested once the tumor size reaches 1.2-1.5 cm in diameter or upon skin ulceration.
4|
Dissect excess, adherent tissue from the tumor using sterile forceps and sterile, curved microscissors. If removing direct xenograft tumor from the mice, start by incising skin at the base of the xenograft tumor. Insert the tips of the microscissor into the incision and gently spread, slowly developing a dissection plane between the skin and the underlying tumor. Extend the incision as needed to completely uncover the tumor and dissect the tumor from adherent deep tissue.
5|
Place the primary human tumor or direct xenograft tumor into 30 ml of sterile, serum-free RPMI medium supplemented with 1× antibiotic/antifungal (antibiotic media), chilled to 4 °C. Wash the specimen twice with 30 ml volumes of serum-free antibiotic media.
6|
Using a sterile 21-blade scalpel, mince the tumor into the smallest possible fragments (1 mm 3 ) and place 0.2 g of tumor (paste-like consistency) into each well of a six-well plate. Place 5 ml of collagenase IV solution into each well. Place the six-well plate(s) into a 37 °C incubator for 2-2.5 h, agitating with a 10-ml pipette every 20 min to augment digestion. During the course of digestion, at each 20-min agitation interval, continue to mince the tumor fragments to the smallest possible pieces.  crItIcal step Do not allow the tumor to dry out; keep immersed in collagenase IV solution at all times.
7|
After digestion, fill each well with 5 ml of sterile, serum-free antibiotic media and mix the suspension with a 25-ml pipette.
8|
Strain the digested tumor solution through a sterile 70-µm cell strainer, collecting the resulting cell solution in a 50-ml centrifuge tube. Discard the filter and associated tissue fragments into an appropriate biohazard trash receptacle. 13| Anesthetize a recipient nude or NOD/SCID mice using ketamine/xylazine cocktail as described in Step 1A(iv).
14|
Shave the left abdominal/flank region of the mouse using clippers and place the mouse on its right side. Paint the left side of the mouse from the base of the neck to the tail with a 70% (vol/vol) ethanol.
15|
Pick up the abdominal skin with forceps and make a 1-cm incision with sterile microscissors slightly medial to the splenic silhouette (Fig. 5a , silhouette outlined by arrows).
16|
Grasp and lift the underlying muscle with forceps and incise to enter the abdominal cavity without injury to the underlying organs (Fig. 5b) . Extend the muscle incision to 1 cm.
17|
Using a pair of blunt-nose forceps, gently grasp the tip of the pancreatic tail and externalize the pancreas/spleen in a lateral direction, exposing the entire pancreatic body and spleen (Fig. 5c) .
18|
Remove the syringe containing the cell suspension (prepared in Step 1B(x) or Step 12) from the ice and agitate to disrupt the cell clumps/clusters.
19|
While gently retracting the pancreas laterally, insert the needle into the tail of the pancreas and pass into the pancreatic head region (Fig. 5d) . Slowly inject 100 µl of cell solution while withdrawing the needle to the mid-body of the pancreas (Fig. 6a) , forming a fluid-filled region within the pancreatic parenchyma (Fig. 6b) . Remove the needle from the pancreas and observe the needle tract for leaks/bleeding.  crItIcal step Ensure the needle is passed parallel to any visible vessels (Fig. 5d, arrows) and along the length of the pancreas. Oblique passage of the needle is likely to injure vessels and result in hemorrhage. (Fig. 7a,b) . Close the overlying skin with a second set of interrupted 3-0 silk sutures (Fig. 7c,d ) and apply antibiotic ointment.
22|
Recover the mice from the effects of the anesthetic. Continue to monitor the temperature, skin color and respiratory rate of mice while under a heat lamp. Mice have recovered from the procedure once they are in a sternal position, respond to external stimuli and freely move about inside the cage.
23|
Monitor mice for tumor growth and general health
• tIMInG
Step (Fig. 8) 28 . However, after successful heterotopic engraftment in first-generation mice, direct xenograft tumor growth at either orthotopic or heterotopic sites should take < 10 weeks in successive mouse generations 28 . Orthotopic tumors derived from xenograft tumors will take 10-15 weeks to reach tumor sizes palpable through the abdominal wall. After the initial growth of patient tumor specimens in immunodeficient mice, the efficiency of orthotopic or heterotopic tumor formation significantly increases to >90% 28 . To amplify the amount of biospecimen available for study, it is common for us to implant xenograft tumor at heterotopic and orthotopic sites in the same mouse. However, we generally discourage this practice if sizeable pancreatic tumors are required for experimental purposes as animals will likely require euthanasia for heterotopic tumor size before the development of substantial pancreatic tumors.
Digestion of direct xenograft tumors into single-cell suspensions largely depends on tumor size and commonly yields between 2 × 10 6 and 5 × 10 6 cells per gram of tumor tissue. However, we have observed that direct xenograft tumors derived from different patients produce varied cell yields when subjected to standard digestion techniques. Variable stromal content and inherent differences between direct xenograft tumor 'lineages' are likely responsible for such inconsistencies. Therefore, we have found it beneficial to alter the concentration of collagenase IV and/or incubation time in collagenase IV solution to maximize cell yields (see Experimental design).
We have largely used cell suspensions derived from direct xenograft tumors for studies involving the selection of subpopulations of cells expressing specific cell surface and/or functional markers 29, 31 . Isolation of such subpopulations requires a single-cell format subject to enrichment by magnetic bead technology and/or fluorescent activated cell sorting. Sorted subpopulations of cells may then be directly injected into the subcutaneous space or pancreatic parenchyma of immunodeficient mice and assessed for various properties, including tumorigenicity and metastasis.
Depending on the cell line, indirect xenograft tumors are palpable at orthotopic or heterotopic sites between 2 and 5 weeks after implantation. We have found the cell lines L3.6pl and Panc-1 to form obvious tumors in the least amount of time (typically 2-3 weeks), whereas other cell lines such as MiaPaCa or AsPC-1 require a minimum of 4-5 weeks for gross tumor formation 11, 12, 31, 32 . 
